United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares of Stock

Posted by Mark Dietrich on May 20th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $567.31, for a total value of $5,673,100.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,708,543.56. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

James Edgemond also recently made the following trade(s):

On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00.
On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $573.03, for a total transaction of $5,730,300.00.
On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $578.58, for a total transaction of $5,785,800.00.
On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $576.93, for a total transaction of $5,769,300.00.
On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $572.61, for a total transaction of $5,726,100.00.
On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $568.83, for a total transaction of $5,688,300.00.
On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The shares were sold at an average price of $575.85, for a total transaction of $209,609.40.
On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The shares were sold at an average price of $572.21, for a total transaction of $5,513,815.56.
On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.86, for a total value of $5,778,600.00.
On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.18, for a total value of $5,771,800.00.

United Therapeutics Stock Performance

Shares of UTHR opened at $566.80 on Wednesday. The stock has a 50 day simple moving average of $561.48 and a 200 day simple moving average of $509.54. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The firm has a market capitalization of $24.06 billion, a PE ratio of 20.92, a P/E/G ratio of 1.83 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the prior year, the firm posted $6.63 earnings per share. United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities research analysts predict that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on UTHR shares. TD Cowen upped their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research note on Monday, March 30th. HC Wainwright upped their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Cantor Fitzgerald upped their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Check Out Our Latest Analysis on UTHR

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently modified their holdings of the business. Janus Henderson Group PLC boosted its stake in shares of United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after buying an additional 70,829 shares during the last quarter. Bull Harbor Capital LLC acquired a new stake in shares of United Therapeutics in the 1st quarter valued at approximately $494,000. Strategic Investment Advisors MI boosted its holdings in shares of United Therapeutics by 20.5% in the 1st quarter. Strategic Investment Advisors MI now owns 9,752 shares of the biotechnology company’s stock valued at $5,782,000 after buying an additional 1,662 shares during the last quarter. Talon Private Wealth LLC acquired a new stake in shares of United Therapeutics in the 1st quarter valued at approximately $3,038,000. Finally, Royal Bank of Canada boosted its holdings in shares of United Therapeutics by 3.3% in the 1st quarter. Royal Bank of Canada now owns 59,152 shares of the biotechnology company’s stock valued at $35,075,000 after buying an additional 1,864 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.